Nice 4c, progressing well margin above my base case of 50% , but YOY sales growth below my base case of 30% growth. CR already flagged by management and coming end of CY though expecting CR at 50c after FDA approval but time will tell. IMO. GLTAH.
Ann: Appendix 4C and Business Activity Report - June-2023, page-5
Add to My Watchlist
What is My Watchlist?